Boston Scientific Corporation (BSX) Stake Raised by Guardian Life Insurance Co. of America

Guardian Life Insurance Co. of America boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.9% during the first quarter, Holdings Channel reports. The fund owned 5,266 shares of the medical equipment provider’s stock after buying an additional 49 shares during the period. Guardian Life Insurance Co. of America’s holdings in Boston Scientific Corporation were worth $131,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Boston Scientific Corporation during the fourth quarter valued at approximately $301,774,000. FMR LLC raised its stake in Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock valued at $4,593,698,000 after buying an additional 13,105,596 shares during the last quarter. Janus Capital Management LLC raised its stake in Boston Scientific Corporation by 17.8% in the fourth quarter. Janus Capital Management LLC now owns 41,575,011 shares of the medical equipment provider’s stock valued at $899,562,000 after buying an additional 6,289,196 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in Boston Scientific Corporation during the first quarter valued at approximately $149,859,000. Finally, Putnam Investments LLC raised its stake in Boston Scientific Corporation by 349.1% in the fourth quarter. Putnam Investments LLC now owns 4,671,346 shares of the medical equipment provider’s stock valued at $101,041,000 after buying an additional 3,631,236 shares during the last quarter. 92.04% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Shares of Boston Scientific Corporation (BSX) traded down 0.053% during trading on Tuesday, hitting $28.235. 1,864,089 shares of the company were exchanged. The company’s 50-day moving average price is $27.03 and its 200 day moving average price is $24.66. The stock has a market cap of $38.67 billion, a P/E ratio of 90.497 and a beta of 1.05. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $0.29 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.30 by $0.01. Boston Scientific Corporation had a return on equity of 23.45% and a net margin of 5.07%. The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.08 billion. During the same period last year, the firm earned $0.28 EPS. The business’s quarterly revenue was up 10.0% on a year-over-year basis. On average, equities analysts predict that Boston Scientific Corporation will post $1.25 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Boston Scientific Corporation (BSX) Stake Raised by Guardian Life Insurance Co. of America” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/2655891/boston-scientific-corporation-bsx-stake-raised-by-guardian-life-insurance-co-of-america.html.

BSX has been the topic of several analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Boston Scientific Corporation in a research report on Thursday, February 23rd. Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Northland Securities reissued a “positive” rating on shares of Boston Scientific Corporation in a research report on Thursday, February 23rd. TheStreet lowered Boston Scientific Corporation from a “b” rating to a “c+” rating in a research report on Thursday, March 16th. Finally, Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Boston Scientific Corporation in a research report on Thursday, February 23rd. Six analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.41.

In related news, EVP Michael P. Phalen sold 79,045 shares of Boston Scientific Corporation stock in a transaction on Wednesday, March 29th. The shares were sold at an average price of $24.55, for a total transaction of $1,940,554.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific Corporation stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $24.87, for a total transaction of $248,700.00. Following the sale, the executive vice president now directly owns 235,846 shares in the company, valued at approximately $5,865,490.02. The disclosure for this sale can be found here. Insiders have sold a total of 217,916 shares of company stock worth $5,606,540 in the last ninety days. 0.74% of the stock is currently owned by insiders.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.